CervoMed reports RewinD-LB trial results for neflamapimod in dementia with Lewy bodies, highlighting missed endpoints and ...

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...

U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial. The drug, ...

Researchers identified 13 proteins that predicted how quickly or slowly a person's brain aged. (Nature Aging) Midlife anxiety ...

CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...

Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks——Favorable ...

CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...

Vivoryon's VIVA-MIND trial echoed the disappointing Alzheimer’s findings of its VIVIAD trial but offers promise in treating ...

Our school teaching resources make it easy to teach and learn about dementia from Key Stage 1 to Key Stage 4. No prior knowledge of dementia is required. All of these resources can be used in class, ...

Dementia is a neurodegenerative disease that has several forms, symptoms, and causes. There’s no cure, but researchers are looking into effective treatments and ways to prevent it. It’s ...

Vivoryon Therapeutics’ glutaminyl cyclase inhibitor has failed a second phase 2 Alzheimer’s disease study this year, leaving ...